Login / Signup

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

Nadine Jackson McClearyWilliam S HarmsenEllana HaakenstadJames M ClearyJeffrey A MeyerhardtZalcberg JohnRichard A AdamsAxel GrotheyAlberto F SobreroEric Van CutsemRichard M GoldbergMarc PeetersJosep TaberneroMatthew T SeymourLeonard B SaltzBruce J GiantonioDirk ArnoldMace L RothenbergMiriam KoopmanHans-Joachim SchmollHenry C PitotPaulo M HoffNiall C TebbuttGianluca MasiJohn SouglakosCarsten BokemeyerVolker HeinemannTakayuki YoshinoBenoist ChibaudelAimery deGramontQian ShiStuart M Lichtman
Published in: JNCI cancer spectrum (2022)
Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.
Keyphrases
  • metastatic colorectal cancer
  • clinical trial
  • physical activity
  • randomized controlled trial
  • stem cells
  • study protocol